[Hypolipidemic effects of alisat and lipostabil in patients with diabetes mellitus].
OBJECTIVE
To study a hypolipidemic action of alisat and lipostabil in patients with non-insulin-dependent diabetes mellitus (NIDDM).


METHODS
Changes in blood lipids were studied in 121 NIDDM patients aged 36-66 years with compensated or subcompensated carbohydrate metabolism on sugar-reducing therapy. The latter consisted of a 52-week course of alisat (600 mg/day) or lipostabil (900 mg/day) in baseline levels of total cholesterol (TC) under 6.5 mmol/l and above 6.5 mmol/l, respectively.


RESULTS
Alisat and lipostal treatments reduced TC levels from 5.4 +/- 25 to 4.77 +/- 0.12 mmol/l and from 7.07 +/- 0.24 to 5.92 +/- 0.30, LDLP cholesterol from 4.0 +/- 0.31 to 2.98 +/- 0.15 mmol/l and 5.54 +/- 0.25 to 4.04 +/- 0.34 mmol/l, respectively. Lipostabil changed LDLP cholesterol and triglycerides from 0.51 +/- 0.05 to 0.33 +/- 0.03 mmol/l and from 2.54 +/- 0.25 to 1.66 +/- 0.15 mmol/l, respectively, while HDLP cholesterol rose from 1.22 +/- 0.10 to 1.55 +/- 0.07 mmol/l. Alisat did not change significantly.


CONCLUSIONS
Adjuvant lipostabil is recommended in combined treatment of NIDDM in marked dyslipidemia, alisat--in moderate dyslipidemia.
Mel'chinskaia
E N
EN
Gromnatskiĭ
N I
NI
Kirichenko
L L
LL
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage*; D005260:Female; D005737:Garlic; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000008:administration & dosage*; D010946:Plants, Medicinal; D014280:Triglycerides / Q000097:blood*
D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005217:Fat Emulsions, Intravenous; D010713:Phosphatidylcholines; D014280:Triglycerides; C005152:lipostabil